Journal articles on the topic 'XP'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'XP.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Cowham, R. "To XP or not to XP?" ITNOW 47, no. 2 (March 1, 2005): 16. http://dx.doi.org/10.1093/itnow/bwi030.
Full textFischer, R., M. Uhl, and H. Vonach. "Nb93(n,xp),Agnat(n,xp), andInnat(n,xp) reactions at 14.1 MeV." Physical Review C 37, no. 2 (February 1, 1988): 578–86. http://dx.doi.org/10.1103/physrevc.37.578.
Full textLitts, Thom, and Jeff Kopaska. "RIP XP." Fisheries 39, no. 4 (April 3, 2014): 151. http://dx.doi.org/10.1080/03632415.2014.893871.
Full textSonia, Archana Singhal, and Hema Banati. "FISA-XP." ACM SIGSOFT Software Engineering Notes 39, no. 3 (June 4, 2014): 1–14. http://dx.doi.org/10.1145/2597716.2597728.
Full textLee, Jeeyun, Do Hoon Lim, Sung Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, et al. "Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial." Journal of Clinical Oncology 30, no. 3 (January 20, 2012): 268–73. http://dx.doi.org/10.1200/jco.2011.39.1953.
Full textIvorra, Wilfrid. "Sur les équations xp+2βyp= z2et xp+2βyp= 2z2." Acta Arithmetica 108, no. 4 (2003): 327–38. http://dx.doi.org/10.4064/aa108-4-3.
Full textFassihi, Hiva, Mieran Sethi, Heather Fawcett, Jonathan Wing, Natalie Chandler, Shehla Mohammed, Emma Craythorne, et al. "Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect." Proceedings of the National Academy of Sciences 113, no. 9 (February 16, 2016): E1236—E1245. http://dx.doi.org/10.1073/pnas.1519444113.
Full textKunwar, Sundar. "Enabling and Limiting factors in eXtreme Programming (XP) with Evaluation Framework." SCITECH Nepal 14, no. 1 (September 9, 2019): 50–62. http://dx.doi.org/10.3126/scitech.v14i1.25534.
Full textMaxmen, Amy. "XP mutant power!" Journal of Experimental Medicine 206, no. 13 (November 30, 2009): 2856. http://dx.doi.org/10.1084/jem.20613iti2.
Full textRapićOtrin, Vesna, Isao Kuraoka, Tiziana Nardo, Mary McLenigan, A. P. M. Eker, Miria Stefanini, Arthur S. Levine, and Richard D. Wood. "Relationship of the Xeroderma Pigmentosum Group E DNA Repair Defect to the Chromatin and DNA Binding Proteins UV-DDB and Replication Protein A." Molecular and Cellular Biology 18, no. 6 (June 1, 1998): 3182–90. http://dx.doi.org/10.1128/mcb.18.6.3182.
Full textStanojevic, Jelena. "On estimation of high quantiles for certain classes of distributions." Yugoslav Journal of Operations Research 25, no. 2 (2015): 299–312. http://dx.doi.org/10.2298/yjor130606013s.
Full textSuman, AHM Khairul Imam, Khadija Begum, Kaniz Rahman, Abu Mohammed Talukder, SM Matiur Rahman, Md Akmat Ali, Nusrath Jahan Hoque, and Mohammad Morshad Alam. "Association of Xanthelasma palpebrarum (XP) with cardiovascular disease (CVD) risk factors." Asian Journal of Medical and Biological Research 5, no. 4 (February 3, 2020): 324–29. http://dx.doi.org/10.3329/ajmbr.v5i4.45271.
Full textVaz-Garcia, Eduarda Santiago, Victor Talarico Leal Vieira, Natasha Pereira da Silva Ferreira Petitet, Edson Jorge Lima Moreira, Hélio Pereira Lopes, Carlos Nelson Elias, Emmanuel João Nogueira Leal Silva, and Henrique dos Santos Antunes. "Mechanical Properties of Anatomic Finishing Files: XP-Endo Finisher and XP-Clean." Brazilian Dental Journal 29, no. 2 (March 2018): 208–13. http://dx.doi.org/10.1590/0103-6440201801903.
Full textPrice, Vera H. "Trichothiodystrophy: Current Concepts." Journal of Cutaneous Medicine and Surgery 1, no. 1 (July 1996): 45–49. http://dx.doi.org/10.1177/120347549600100113.
Full textMiao, Junjie, Changchun Chai, Wei Zhang, Yanxing Song, and Yintang Yang. "First-Principles Study on Structural, Mechanical, Anisotropic, Electronic and Thermal Properties of III-Phosphides: XP (X = Al, Ga, or In) in the P6422 Phase." Materials 13, no. 3 (February 4, 2020): 686. http://dx.doi.org/10.3390/ma13030686.
Full textLee, J., W. Kang, D. Lim, J. Park, Y. Park, H. Lim, T. Sohn, J. Noh, J. Bae, and S. Kim. "Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 4537. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4537.
Full textFernández-Sánchez, Javier. "Against a clausal ellipsis account of all stripping strings in Spanish." Poznan Studies in Contemporary Linguistics 55, no. 1 (March 26, 2018): 53–87. http://dx.doi.org/10.1515/psicl-2019-0003.
Full textRana, MS, MM Rahman, UK Rima, and NS Juyena. "General anaesthesia of indigenous pigs in Bangladesh." Bangladesh Veterinarian 30, no. 2 (March 6, 2014): 46–53. http://dx.doi.org/10.3329/bvet.v30i2.18254.
Full textKarentz, D., and J. E. Cleaver. "Repair-deficient xeroderma pigmentosum cells made UV light resistant by fusion with X-ray-inactivated Chinese hamster cells." Molecular and Cellular Biology 6, no. 10 (October 1986): 3428–32. http://dx.doi.org/10.1128/mcb.6.10.3428.
Full textKarentz, D., and J. E. Cleaver. "Repair-deficient xeroderma pigmentosum cells made UV light resistant by fusion with X-ray-inactivated Chinese hamster cells." Molecular and Cellular Biology 6, no. 10 (October 1986): 3428–32. http://dx.doi.org/10.1128/mcb.6.10.3428-3432.1986.
Full textMartens, M. C., L. Boeckmann, and S. Emmert. "Genetisch bedingte Hauterkrankungen – Xeroderma pigmentosum und das CEDNIK-Syndrom." Aktuelle Dermatologie 46, no. 08/09 (August 20, 2020): 375–78. http://dx.doi.org/10.1055/a-1148-3867.
Full textRothkopf, Michael. "An Algorithmic Approach for Lipid Metabolism and Management of Patients with Xanthelasma Palpebrarum (XP)." Current Developments in Nutrition 4, Supplement_2 (May 29, 2020): 1140. http://dx.doi.org/10.1093/cdn/nzaa055_025.
Full textAlakshar, Asmaa, Abdul Rahman Mohammed Saleh, and Mehmet Omer Gorduysus. "Debris and Smear Layer Removal from Oval Root Canals Comparing XP-Endo Finisher, EndoActivator, and Manual Irrigation: A SEM Evaluation." European Journal of Dentistry 14, no. 04 (August 10, 2020): 626–33. http://dx.doi.org/10.1055/s-0040-1714762.
Full textSugimoto, Naotoshi, Tetsuhiro Yoshinami, Sachiko Yamamoto, Toshinari Yagi, and Fumio Imamura. "Does capecitabine plus cisplatin (XP) give advanced or recurrent gastric cancer (AGC) patients higher early tumor shrinkage (ETS) rate than S1 plus cisplatin (SP) with safety?" Journal of Clinical Oncology 33, no. 3_suppl (January 20, 2015): 172. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.172.
Full textTakeno, Atsushi, Youichi Makari, Shunji Endo, Jin Matsuyama, Ryohei Kawabata, Naotoshi Sugimoto, Hirokazu Taniguchi, et al. "Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial." Journal of Clinical Oncology 36, no. 4_suppl (February 1, 2018): 102. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.102.
Full textBahrudin, Ida Aryanie, Rafizah Mohd Hanifa, Mohd Ezree Abdullah, and Muhammad Firdaus Kamarudin. "Adapting eXtreme Programming Approach in Developing Electronic Document Online System (eDoc)." Applied Mechanics and Materials 321-324 (June 2013): 2938–41. http://dx.doi.org/10.4028/www.scientific.net/amm.321-324.2938.
Full textGengler, Barbara. "XP a National Threat?" Network Security 2001, no. 11 (November 2001): 5. http://dx.doi.org/10.1016/s1353-4858(01)01111-4.
Full textJ.-M.M. "XP Centaur en majesté." Revue Francophone des Laboratoires 2007, no. 388 (January 2007): 10. http://dx.doi.org/10.1016/s1773-035x(07)80003-7.
Full textSchwarz, Diemo, and Etienne Brunet. "theconcatenator: Placard XP edit." Leonardo Music Journal 18 (December 2008): 89–90. http://dx.doi.org/10.1162/lmj.2008.18.89b.
Full textReifer, D. J. "XP and the CMM." IEEE Software 20, no. 3 (May 2003): 14–15. http://dx.doi.org/10.1109/ms.2003.1196314.
Full textTorre, Alberto C. de la. "The ubiquitous XP commutator." European Journal of Physics 27, no. 2 (January 3, 2006): 225–30. http://dx.doi.org/10.1088/0143-0807/27/2/005.
Full textFraser, Steven, and Giancarlo Succi. "XP requirement negotiation workshop." ACM SIGAPP Applied Computing Review 10, no. 1 (April 2002): 26–31. http://dx.doi.org/10.1145/568235.568239.
Full textYu, Jeong Il, Hee Chul Park, Jeeyun Lee, Changhoon Choi, Won Ki Kang, Se Hoon Park, Seung Tae Kim, et al. "Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer." Cancers 12, no. 4 (April 10, 2020): 943. http://dx.doi.org/10.3390/cancers12040943.
Full textPoulin, Yves, Robert Bissonnette, Christina Juneau, Kim Cantin, Rejean Drouin, and Patrice E. Poubelle. "XP-828L in the Treatment of Mild to Moderate Psoriasis: Randomized, Double-Blind, Placebo-Controlled Study." Journal of Cutaneous Medicine and Surgery 10, no. 5 (September 2006): 241–48. http://dx.doi.org/10.2310/7750.2006.00049.
Full textBeroual, Nabil, and Ahmed Bendjeddou. "On a Predator–Prey System with Holling Functional Response: xp/(a + xp)." National Academy Science Letters 39, no. 1 (October 12, 2015): 43–46. http://dx.doi.org/10.1007/s40009-015-0400-6.
Full textYang, Tianyu, Can Ding, Richard W. Ziolkowski, and Y. Jay Guo. "A Terahertz (THz) Single-Polarization-Single-Mode (SPSM) Photonic Crystal Fiber (PCF)." Materials 12, no. 15 (July 31, 2019): 2442. http://dx.doi.org/10.3390/ma12152442.
Full textLee, Ji Eun, Myung Ah Lee, Tae Ho Hong, In Seok Lee, and Young Kyoung You. "Comparison of the efficacy between the gemcitabine/cisplatin (GP) and capecitabine/cisplatin (XP) for the advanced biliary tract cancer: Retrospective analysis in a single institution." Journal of Clinical Oncology 30, no. 4_suppl (February 1, 2012): 365. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.365.
Full textDe Braud, Filippo G., and Wentao Jason Wu. "A dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of mTORC1/2 inhibitor XP-105 (BI 860585) as monotherapy and in combination with exemestane or paclitaxel in patients (pts) with advanced solid tumors." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 3127. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.3127.
Full textBen Rekaya, Mariem, Nadia Laroussi, Olfa Messaoud, Mariem Jones, Manel Jerbi, Chokri Naouali, Yosra Bouyacoub, et al. "A Founder Large Deletion Mutation in Xeroderma Pigmentosum-Variant Form in Tunisia: Implication for Molecular Diagnosis and Therapy." BioMed Research International 2014 (2014): 1–8. http://dx.doi.org/10.1155/2014/256245.
Full textKrasikova, Yuliya, Nadejda Rechkunova, and Olga Lavrik. "Nucleotide Excision Repair: From Molecular Defects to Neurological Abnormalities." International Journal of Molecular Sciences 22, no. 12 (June 9, 2021): 6220. http://dx.doi.org/10.3390/ijms22126220.
Full textPoddar, Rakshapada, Subhradeep Chakraborty, and Sudipta Chattopadhyay. "Improved Cross Polarization and Broad Impedance Bandwidth from Simple Single Element Shorted Rectangular Microstrip Patch: Theory and Experiment." Frequenz 70, no. 1-2 (January 1, 2016): 1–9. http://dx.doi.org/10.1515/freq-2015-0105.
Full textGarcía-García, J. I., D. Marín-Aragón, and A. Vigneron-Tenorio. "Union of Sets of Lengths of Numerical Semigroups." Mathematics 8, no. 10 (October 15, 2020): 1789. http://dx.doi.org/10.3390/math8101789.
Full textMulyantari, Kadek, Aryati ., and M. Y. Probohoesodo. "PENEMUAN (DETEKSI) ANTIBODI UNTUK ANTIGEN TUBERKULOSIS MENGGUNAKAN METODE IMUNOKROMATOGRAFI DI PENDERITA TUBERKULOSIS PARU." INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 14, no. 3 (March 16, 2018): 127. http://dx.doi.org/10.24293/ijcpml.v14i3.938.
Full textKang, Y., W. K. Kang, D. B. Shin, J. Chen, J. Xiong, J. Wang, M. Lichinitser, M. Philco, T. Suarez, and J. Santamaria. "Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): LBA4018. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.lba4018.
Full textArmelini, Melissa G., Keronninn M. Lima-Bessa, Maria Carolina N. Marchetto, Alysson R. Muotri, Vanessa Chiganças, Ricardo A. Leite, Helotonio Carvalho, and Carlos F. M. Menck. "Exploring DNA damage responses in human cells with recombinant adenoviral vectors." Human & Experimental Toxicology 26, no. 11 (November 2007): 899–906. http://dx.doi.org/10.1177/0960327107083556.
Full textBeal Partyka, Raul, Jeferson Lana, and Rosilene Marcon. "A XP e o Itaú Unibanco: dos Produtos de Investimento a Desbancarização." Administração: Ensino e Pesquisa 21, no. 2 (May 1, 2020): 214–38. http://dx.doi.org/10.13058/raep.2020.v21n2.1749.
Full textDrouin, Réjean, Éric Lamiot, Kim Cantin, Sylvie F. Gauthier, Yves Pouliot, Patrice E. Poubelle, and Christina Juneau. "XP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasisThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products." Canadian Journal of Physiology and Pharmacology 85, no. 9 (September 2007): 943–51. http://dx.doi.org/10.1139/y07-084.
Full textTruckenbrodt, Hubert. "On the Relation between Syntactic Phrases and Phonological Phrases." Linguistic Inquiry 30, no. 2 (April 1999): 219–55. http://dx.doi.org/10.1162/002438999554048.
Full textOnishi, Masazumi, Kanako Tsunoda, Fumihiko Maeda, Shinichi Moriwaki, and Hiroo Amano. "Angiosarcoma of the Auricle in a Patient with Xeroderma Pigmentosum Variant." Case Reports in Dermatology 12, no. 2 (August 18, 2020): 144–49. http://dx.doi.org/10.1159/000508884.
Full textLueck, H., G. V. Minckwitz, A. Du Bois, I. Schrader, J. Huober, V. Heilmann, M. Beckmann, et al. "Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 517. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.517.
Full text